No Chemo, No Radiation: South Korean Team Reverses Cancer at the Cellular Level

Cancer Reimagined: Scientists Reprogram Tumors Into Healthy Cells Without Chemo

Major Medical Breakthrough: South Korean Scientists Transform Cancer Cells into Healthy Ones Without Chemo or Radiation

Instead of destroying tumor cells—an approach that often harms surrounding healthy tissue and causes severe side effects—South Korean researchers have developed a groundbreaking method that reprograms cancer cells into stable, non-cancerous ones. Published in Advanced Science, their study reveals how they redirected cancer cells away from unchecked growth and restored them to a differentiated, healthier state.

In a groundbreaking discovery that could revolutionize cancer treatment, South Korean scientists have managed to reverse the malignant behavior of cancer cells without destroying them. Rather than using chemotherapy or radiation, the researchers reprogrammed the cancer cells to function like healthy tissue. Tested on colorectal cancer, their experimental approach doesn’t eliminate tumors — it restores them.

Leading this pioneering research is Professor Kwang-Hyun Cho and his team at the Korea Advanced Institute of Science and Technology (KAIST). They employed a cutting-edge computational model known as a digital twin to guide the transformation of cancer cells.

While traditional cancer treatments focus on destroying tumor cells—often harming healthy tissue and causing severe side effects—Cho’s team took a radically different approach. In a study published in Advanced Science, they described a technique that redirects cancer cells from uncontrolled growth toward a stable, differentiated state.

Central to their strategy is a computational system called BENEIN (Boolean Network Inference and Control), which simulates gene interactions within individual cells. By analyzing these networks, BENEIN pinpoints crucial genetic regulators that determine whether a cell behaves abnormally or functions like healthy tissue.

The study identified three key genetic regulators — MYB, HDAC2, and FOXA2 — as central to reprogramming cancer cells. “Simultaneously silencing MYB, HDAC2, and FOXA2 strongly promotes differentiation into normal-like cells,” the researchers stated.

Analyzing data from 4,252 intestinal cells, the team built a gene interaction network comprising 522 components. Simulations suggested that deactivating these three genes would stop cancer cells from multiplying — a prediction confirmed in both colorectal cancer cell lines and animal models.

In human colorectal cell lines HCT-116, HT-29, and CACO-2, the combined knockdown of the three genes significantly reduced cell growth compared to targeting any single gene. When these modified cells were implanted into mice, the resulting tumors were notably smaller in both size and weight than those in the untreated control group.

Further analysis revealed that the treated cancer cells began expressing markers typically found in healthy intestinal cells, such as KRT20 and VDR, while cancer-related pathways like MYC and WNT were significantly suppressed. Their gene expression profiles closely resembled those of normal tissue samples found in The Cancer Genome Atlas.

The BENEIN framework also demonstrated versatility beyond cancer. It successfully identified critical regulators in other biological systems, including mouse hippocampus development and T cell activation, outperforming established tools like SCENIC and VIPER.

Despite some remaining challenges—such as adapting the technique to different tissue types and ensuring long-term stability of reprogrammed cells—the implications are groundbreaking. If further refined and translated into clinical practice, this approach could mark a paradigm shift in cancer therapy, moving from cell destruction to cellular reprogramming.

The study, titled "Control of Cellular Differentiation Trajectories for Cancer Reversion," was published in Advanced Science on December 11, 2024.